Chiara Nozzoli

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Cardiovascular Complications and Subclinical Myocardial Dysfunction in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Cardiovascular Complications and Subclinical Myocardial Dysfunction in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Journal: Cancers

Published: April 25, 2026

Use of an unrelated cord blood unit as an emergency rescue graft after last-minute donor collection cancellation.

Use of an unrelated cord blood unit as an emergency rescue graft after last-minute donor collection cancellation.

Journal: Bone marrow transplantation

Published: April 25, 2026

Safety of Prophylactic Anakinra in Patients Treated with CD28-Based CD19 Chimeric Antigen Receptor-T Cells for R/R B-Cell Lymphoma.

Safety of Prophylactic Anakinra in Patients Treated with CD28-Based CD19 Chimeric Antigen Receptor-T Cells for R/R B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 14, 2026

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Journal: Bone marrow transplantation

Published: March 02, 2026

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 22, 2026

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

Journal: Bone marrow transplantation

Published: January 21, 2026

Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study.

Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study.

Journal: The Lancet. Infectious diseases

Published: January 12, 2026

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Late complications after autologous HSCT for autoimmune diseases: a retrospective survey from the autoimmune diseases working party (ADWP), transplant complications working party (TCWP) and paediatric diseases working party (PDWP) of the european society for blood and marrow transplantation (EBMT).

Journal: Bone marrow transplantation

Published: December 10, 2025

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Journal: Haematologica

Published: September 29, 2025

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology

Published: August 22, 2025

Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study.

Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: May 26, 2025

Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction.

Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction.

Journal: Cancers

Published: May 23, 2025

Showing 1-12 of 60

Last Updated: 09/26/2026